Composition for compensation of growth retardation

FIELD: veterinary science.

SUBSTANCE: composition comprises a source of lipids, containing fatty acids, also n-3 long-chain polyunsaturated fatty acide (LC PUFA-LC PUFA), prebiotic fibres, such as fructo-oligosaccharides, inulin, galacto-oligosaccharides, gum arabic and sialo-oligosaccharides or their mixture and a probiotic bacterial strain, in particular, Lactobacillus paracasei CNCMI-2116 or Lactobacillus rhamnosus ATCC 53103 or Bifidobacterium lactic CNCM 1-3446 and additionally contains n-6 long-chain polyunsaturated fatty acid in specified quantities. At the same time the mixture of prebiotic fibres may contain 40% - 60% of gum arabic, 10% - 20% of inulin and 30% - 40% of fructo-oligosaccharide.

EFFECT: invention makes it possible to compensate for growth retardation without use of synthetic hormones and increasing calorie consumption.

5 dwg, 2 tbl, 2 ex

 

The technical field to which the invention relates.

The present invention relates to compositions that promote compensation stunted growth in young mammals, whose growth has slowed due to the fact that the young mammal subjected to physical or mental stress, and to the use of such compositions. In particular, the present invention relates to compositions containing a synergistic combination of ingredients that contribute to the compensation of stunting.

Prior art

For many years there was generally accepted opinion that the growth of young mammals experiencing stress as a result of physical disease or injury or psychological trauma, often interrupted. If you provide such a young mammal quick recovery and good nutrition, it could compensate for the growth that would take place during times of stress, and such a sudden spurt (sudden leap) growth known as "delay compensation growth." However, usually this does not happen. For example, a young mammal may suffer from anorexia (lack of appetite) as during illness or injury, and the consequences of stress, and therefore the consumption of food may be limited. In severe cases it may happen that the animal Niko is Yes will not reach the physical body, which it could achieve, not postlady from stress.

This phenomenon can be observed in young mammals, including humans, from infancy and throughout that period of life in which they grow. Although the provision of compensation slowed down during periods of physical or mental stress growth is highly desirable, it is also important that growth retardation was not excessive, as there are indications that periods of very rapid and/or extensive delays growth, especially in infancy may be associated with risk of obesity in the future.

Thus, the aim of the present invention is to provide compositions suitable for optimal compensation stunted growth in young mammals that have been subjected to physical or mental stress.

Summary of the invention

In the course of research that led to the present invention, the authors present invention has unexpectedly found that the reception of the specific combination of ingredients helps to compensate for the stunted growth in young mammals exposed to stress.

Thus, in a first aspect the present invention provides a nutritional composition that can compensate the delay of the growth, which includes a source of lipids, the soda is containing fatty acids, n-3 long-chain polyunsaturated fatty acid (DC PUFA → LC-PUFA)present in amount of at least 0.01% of the fatty acids in the composition, prebiotic fiber in the amount of at least 0.001 g/g of the composition and probiotic bacterial strain in the range from 103up to 1011CFU/g of composition.

In a second aspect the present invention provides the use of n-3 long-chain polyunsaturated fatty acids (DC PUFA), prebiotic fiber and probiotic bacterial strain for the production of the nutritional composition or the medicinal product for compensation of stunting among the sick and convalescent young mammals.

The present invention provides a further method of compensation stunting the patient and recovering the young of a mammal, which provides for the introduction of the needy in this young mammal a therapeutically effective amount of a composition containing n-3 DC polyunsaturated fatty acids, prebiotic fiber and probiotic bacterial strain.

The advantage of the present invention is that it provides the possibility of compensation of stunting without the use of synthetic hormones, and using a synergistic combination of ingredients of the food quality. In addition, young mammals, experiencing stress, the frequent lack of appetite and don't want or can't consume large amounts of calories; the advantage of the present invention is that it provides an opportunity to compensate for the delay of growth without increasing calorie intake, when the balance of lean body mass and mass of body fat and without provoking obesity.

Figures

Figure 1 shows the evolution of body weight in 6 groups of rats fed different diets during the period from the 15th through the 21st postnatal postnatal day (PND).

Figure 2 shows the evolution of body weight in the same groups of rats, as in figure 1, fed different rations during the period from 21st to 36th PND.

Figure 3 shows the feed intake by the same groups of rats during the period from 21st to 36th PND.

Figure 4 shows the body mass index in g/cm2for six groups of rats at the 36th PND.

Figure 5 shows the mass in g of fatty deposits in the epididymis (the epididymis and peritoneum of six groups of rats at the 36th PND.

Detailed description of the invention

In the present description the following terms are used, the values of which are disclosed below.

"Probiotic bacterial strain" means a feed additive with living microorganisms that have beneficial effects on the animal host by improving its intestinal microbial balance (from "Probiotics in Man and Animals", J. Appl. Bacteriol. 66: 365-378,1989).

"Prebiotic" means unassimilated food ingredient that beneficially affects the host selectively stimulating the growth and/or and the efficiency of one species or a limited number of bacteria in the colon and improving thus, the health of the host (from "Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics", J Nutr. 125: 1401-1412, 1995).

"Young mammal" means any mammal, including human and animal companions of man, from birth to the age in which the mammal listed species reaches its full physical physique.

Preferably the probiotic bacterial strain is a strain of Lactobacillus or Bifidobacterium. Suitable for this purpose, the strains of Lactobacillus include Lactobacillus rhamnosus ATCC 53103, provided by the company Valio OY, Finland, and Lactobacillus paracasei CNCM I-2116, the latter is especially preferred. Suitable for this purpose, the strains include Bifidobacterium Bifidobacterium longum BB536 provided by the company Morinaga, Japan; Bifidobacterium lactis provided by the firm Christian Hansen of Denmark, Denmark, under the trade mark Bb12, Bifidobacterium lactis CNCM I-3446. Can be used in combinations of strains, and the combination with Lactobacillus Bifidobacterium are particularly preferred. The selected strain or strains may be introduced into the composition in the form of a powder obtained by freeze or spray drying. Alternative nutritional composition may further comprise fermentary food product, such as milk and cereals, and for fermentation of the specified food product can be used probiotic bacterial piece is mm

Prebiotic fiber can be selected from fructo-oligosaccharides (FOS → FOS), galactooligosaccharides (STATE → GOS), valorisation, xylooligosaccharides, inulin, gum Arabic, guar gum, resistant starch, oligosaccharides, derived from milk, and mixtures thereof. Preferred prebiotic fibers are fructo-oligosaccharides, inulin, gum Arabic and galactooligosaccharide, in particular a mixture of from 70% to 95% of galactooligosaccharide, from 30% to 5% of fructooligosaccharide and from 40% to 60% gum Arabic; from 30% to 40% of fructooligosaccharide and from 10% to 20% inulin. Suitable for this purpose, galactooligosaccharides is galactooligosaccharide implemented in the market firm Borculo Domo Ingredients under the brand name Vivinal GOS 10. Suitable fructooligosacharides is fructooligosaccharide implemented in the market the company Orafti S.A. under the trademark Raftilose P95. Suitable inulin is inulin, which is implemented in the market the company Orafti S.A. under the trademark Raftiline HP. Suitable with Arabic gum is gum Arabic, which is implemented on the market company CNI under the trademark FiberGum P. Preferably prebiotic fiber or fibers is/are present in a total amount of from 0.02 to 0.05 g/g of composition.

The composition contains at least one n-3 DC polyunsaturated fatty acids such as C20 or C22 n-3 fatty acid. C20 or C22 n-3 DC PUFA preferably Pris is tstuat in number, at least 0.1 wt.% all fatty acids in the composition. Preferably n-3 DC DHA is docosahexaenoic acid (DHA → DHA, C22:6, n-3).

Preferably the composition also contains n-6 polyunsaturated fatty acids such as C20 or C22 n-6 fatty acid. Suitable for this purpose n-6 DC PUFA is arachidonic acid (AA → AA, C20:4, n-6). C20 or C22 n-6 DC PUFA is preferably present in amount of at least 0.1 wt.% all fatty acids in the composition.

The ratio (n-6):(n-3) is preferably from 1:2 to 8:1, more preferably from 4:1 to 8:1. Source DC polyunsaturated fatty acids can be, for example, lipids, egg, mushroom oil, cod-liver oil with low content of eicosapentaenoic acid (EPA → EPA) or oil of seaweed.

The composition may be in the form of nutritional supplements or can serve as a complete food. Examples of suitable bases for the nutritional composition according to the present invention are milk, yogurt, curd, cheese, fermented milk drinks and milk products, fermented products are corn-based, dry milk products, a mixture of baby food and compositions for oral and enteral feeding.

In a preferred variant embodiment of the present invention provides an infant formula or pediatric nutritional composition. In addition to energetichesk the th combination of ingredients, as described above, it may contain a source of protein and/or a source of carbohydrate.

The protein source may be any suitable dietary protein, such as animal protein (such as milk proteins, meat proteins, egg protein), vegetable protein (such as soy, wheat, rice or pea protein), mixtures of free amino acids or a combination thereof. Milk proteins such as casein and whey proteins are particularly preferred. In a preferred variant embodiment of pediatric composition of the protein source provides from 7% to 14% of the energy of the composition.

In pediatric composition source of lipids preferably provides from 30% to 50% of the energy mix. The lipids that make up the source of lipids, can be any suitable for this purpose, the fat or mixture of fats. Particularly suitable are vegetable oils such as soybean oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil, lecithins, and the like, If necessary, can also be added animal fats such as milk fat. Preferably the source of fat contains at least 15% medium chain triglycerides, and its fatty acid profile comprises from 20% to 40% saturated fatty acids, from 45% to 69% monounsaturated fatty acids and from 10% to 25% polyunsaturated the IRNA acids.

If pediatric composition includes a source of carbohydrate, a source of carbohydrate preferably provides from 40% to 60% of the energy of the composition. Can be any suitable carbohydrate or mixture of carbohydrates, such as sucrose, lactose, glucose, fructose, dried corn syrup and maltodextrins.

The composition may include an accepted way of necessary vitamins and minerals so that it meets the relevant requirements. Optionally, the composition may be administered one or more emulsifiers food quality, for example esters diatsetilvinny acid and mono-/diglycerides, lecithin and mono and diglycerides. Similarly, may include suitable salts and stabilizers.

Preferably the composition is intended for enteral administration, for example in powder form, the recovered water. Restored the composition can be administered orally or by nasogastric tube. It can be prepared in any suitable manner, for example by mixing in appropriate proportions of the source of dietary protein, carbohydrate and fat. Optionally, the mixture may comprise emulsifiers. At the same time can be added vitamins and minerals, but usually they are added later in order to avoid decomposition by heat. Lipophilic vitamins, Amul gatory etc. can be dissolved before mixing in the source of fat. Can then be mixed with water, preferably water processed by reverse osmosis method, to prepare a liquid mixture. Water temperature is usually from about 50°C to 80°C to facilitate dispersion of the ingredients. To prepare a liquid mixture can be used commercially available reducers. Thereafter, the liquid mixture is homogenized, for example, in two stages.

Then the liquid mixture is subjected to heat treatment to reduce bacterial load. For example, the liquid mixture may be heated quickly to a temperature of about from 80°C to 150°C for about from 5 seconds to 5 minutes. This can be done through the injection of steam, autoclave or heat exchanger, for example in a plate heat exchanger. Thereafter, the liquid mixture is cooled to a temperature of about from 60°C to 85°C, for example, by instant cooling. Then the liquid mixture may again gomogeniziruetsya, for example, in two stages at a pressure of about 7 MPa to 40 MPa in the first stage and from about 2 MPa to 14 MPa in the second stage. Gomogenizirovannogo mixture may optionally be cooled for later addition of temperature-sensitive components, such as vitamins and minerals. At the same time, it is convenient to standardize gomogenizirovannogo with the ect on the pH and solids content.

Gomogenizirovannogo the mixture is fed into a suitable drying apparatus such as a spray drier or freeze drier, and converted into powder. The powder should have a moisture content below about 5 wt.%. Probiotic bacterial strain is convenient to add it at this point by dry mixing.

If you want to prepare a liquid composition, gomogenizirovannogo the mixture is preferably poured aseptically into suitable containers. Aseptic filling of containers can be carried out by pre-heating the homogenized mixture (for example, to a temperature of from about 75°C to 85°C) and subsequent injection of steam in gomogenizirovannogo mixture to raise the temperature to about 140°C-160°C, for example, about 150°C. Then gomogenizirovannogo mixture can be cooled, for example by instant cooling to a temperature of from about 75°C. to 85°C. After this gomogenizirovannogo the mixture can gomogeniziruetsya, then cooled approximately to room temperature and poured into containers. Suitable apparatus for the implementation of the aseptic filling of this kind is issued by the industry. The liquid mixture may be in the form of ready-to-use mixture having a solids content from about 10% to 14 wt.% or may be in the form of concentrate, soda is the content of dry substances which usually amounts to from about 20% to 26 wt.%. In the liquid mixture can be added flavorings. In the case of liquid mixtures of probiotic bacterial strain is preferably provided separately packaged, intended for mixing immediately before use of liquid compositions.

The amount of composition required for feeding the young mammal, will vary depending on such factors as the patient's condition, body weight and age, and whether the composition is the only source of food. In most cases, be considered sufficient amount of the composition that provides the patient the amount of protein from 1 to 4 g of protein/kg of body weight/day, supplemented with ingredients according to the present invention in amounts specified above. If the nutritional composition is used as an additive to other foods, the amount of the nutritional composition, taken daily, can be reduced accordingly.

Below are given to illustrate the invention examples, not limiting its scope.

Example 1

An example of the composition of the pediatric nutritional composition according to the present invention is given below. This part is only to illustrate the invention.

The composition has the following composition (per 100 g of powder): total fat - 18,3 g total protein - to 13.9 g, total carbohydrates - 59,2 g, about asenne AK oil (mushroom) - 0.2 g DHA enriched oil (cod-liver oil with low content of EPA) - 0.2 g gum Arabic/FOS/inulin(51%/34%/15%) - 12 g, L.paracasei CNCM I-2116 (Nestlé, powder spray drying, 10-12 CFU/g) - 0.1 g, .longum BB536 (Morinaga, powder spray drying, 5×10-12 CFU/g) - 0.1 g, sodium - 222 mg, potassium 500 mg, chloride - 370 mg, phosphorus - 278 mg, calcium - 417 mg, magnesium - 53 mg, manganese - 231 mcg, vitamin a - 680 ME, vitamin D - 180 ME, vitamin E - 6,8 ME, vitamin C 36 mg, vitamin K1 - 18 μg, vitamin B1 - 0.27 mg, vitamin B2 - 0.36 mg, vitamin B6 - 0.36 mg, Niacin - 2.7 mg, folic acid - 91 mcg, Pantothenic acid 1.4 mg, vitamin B12 - of 0.68 μg, Biotin - 6,8 mcg, choline - 110 mg, taurine - 36 mg, carnitine - 18 mg iron 4.5 mg, iodine - 36 mcg, copper - 0.36 mg and zinc - 4,5 mg

The mixture is recovered by mixing 221 g of the powder with 779 ml of water to obtain 1 l of ready to use product. The above composition can vary depending on the requirements of the national legislation concerning the amounts of specific ingredients. Other trace elements (e.g. selenium, chromium, molybdenum, fluoride) may be added in an appropriate amount depending on age.

Example 2

The following experiments show the effect on newborn rats exposed to stress, feeding a nutrient composition according to the invention, the nutritional compositions, supplemented by individual components of the composition to solenoidality and nutrient composition without additives.

Animals

Pervertie pregnant female rats, Long-Evans Hooded were purchased from Janvier (France), delivered to the place of the animals at 10 and 11 days of pregnancy. Before delivery, they were kept in individual cages under constant temperature and humidity, and maintain the cycle of 12:12 dark:light. Feed and water were given ad libitum. The conditions maintained during the whole experiment. Later, one day after delivery (postnatal day 2=PND2), females were removed from maternity cells and determined the sex of the rats. Standard socket-litter 8 of rats-males were formed randomly for nursing offspring.

Neonatal stress

Mares and their offspring included in one of two modes of curing: 1) in groups with the division of dams and offspring - 180-minute period daily separation of females and offspring, starting from the 2nd to the 14th PND (MS group), or 2) in the control group with the holding in the hands exposed daily manipulation (weighing and 15-minute hold in the hand), but without division of dams and offspring (NS group). At 9am females were removed from the cells in which they were kept, and were placed in a cell to wait for 3-hour period of separation of females and offspring (MS uterus) or 15-minute period holding in his hands (NS uterus). Each MS litter were removed from the nest, weighed and placed as a group in an isolated cell neighbouring the first room. Isolated cells were kept at 32,0±0,5°C. after a period of separation of rat pups were returned to the cages in which they were being held and moved (rolled) dirty litter before reunite them with Vyazovaya their uterus. With the nest with offspring from the NS group received the same way, but instead of the 3-hour period separating them gently picked up for 15 minutes. Just had 5 groups of MS rats and 1 NS group of rats, each group consisted of 8 rats.

Fifty percent of soiled bedding in the cage, which contained the rats were replaced with clean bedding once a week.

Experimental methods

All the rats in 5 MS groups were completely separated from Vyazovaya their mares on the 15th PND and after weaning were placed on a control diet or diets with additives 1-4. The rats from each of these groups contained together (5 animals/cage). NS group was left with vyhazhivanii their Queens to 21 PND. In the period between the 15th and 21st PND weight of all the rats were monitored daily. 21 PND rat NS group were placed on a control diet. From this day until the end of the experiment (36th PND), all the rats were placed individually. In the period from the 15th to the 36th PND the MS rats groups was continued to be fed the same diet to which they were transferred after weaning. The feed was replaced with a fresh batch of each of the e morning, and all the rats had received ad libitum.

Diets

Animals in the MS groups were received in the period from the 15th to the 36th PND adapted nutrient semisynthetic diets (modified AIN 93 G), the composition of which is presented in table 1 (see below). Diets with additives contain one or more of the following functional ingredients: Lactobacillus paracasei CNCM I-2116 (4×1010SOME in 0.8 ml of spent culture medium/100 g diet); 0.4 g inulin/100 g diet (Raftiline HP, Orafti SA, Belgium); 3.6 g GOS (galacto-oligosaccharides)/100 g of diet (Vivinal® GOS 10, Borculo Domo Ingredients, Netherlands); 2 g arachidonic acid/100 g of diet (ARASCO® Martek, USA) and 2 g of docosahexaenoic acid (DHASCO® Martek, USA). The control diet contained fresh MRS instead of the probiotic in the spent culture medium, lactose (Fluka, 61340), an increased amount of maltodextrin (Glucidex D12, Roquette Freres, France) instead of prebiotic and increased amounts of cocoa butter and corn oil, replacing docosahexaenoic and arachidonic acid. Similarly, diets with additives containing only one of the ingredients of the composition according to the invention, include an appropriate placebo ingredient.

td align="center"> Control
Table 1
The composition of the diets
IngredientDiet with supplements 1Diet with additives 2Diet with additives 3Diet with supplements 4
K-Caseinate (g)20,0020,0020,0020,0020,00
Corn starch (g)32,9532,9532,9532,9532,95
Maltodextrin (g)20,7412,5812,5812,5812,58
Sucrose (g)10,0010,0010,0010,0010,00
Lactose (g)4.26 deaths
Raftiline HP (g)0,42 0,42
Vivinal GOS 10 (g)12,0012,00
The mixture of fats (g) (see below)7,007,007,007,007,00
A mixture of minerals (AIN-93-G)3,503,503,503,503,50
Vitamin mixture (AIN-93-VX)1,001,001,001,001,00
L-cysteine (g)0,300,300,300,300,30
Challengejakarta DAB 100,250,250,250,250,25
MRS (ml)0,80is the 0,800,80
L.paracasei CNCM I-2116 (ml)0,800,80

Table 2
The mixture of fats
Ingredient (g/100 g of a mixture of fats)ControlDiet with supplements 1Diet with additives 2Diet with additives 3Diet with supplements 4
Soybean oil25,1226,4426,4425,1225,12
Trisun 802,592,59
Cocoa butter30,2627,1227,1230,2630,26
Corn oil44,6334,2234,2244,6344,63
ARASCO4,704,70
DHASCOis 4.93is 4.93

Statistical analysis

Data were expressed as mean ±SEM. Normality and homoscedasticity (constant average variance) of the data was tested for each group. To assess differences between groups in each age category body weight in the period from the 15th through the 21st PND, body mass index and fat compared one method ANOVA with subsequent determination of the minimum significant difference Fisher (Fischer's Least Significant Difference (LSD)). To assess differences between groups of curves of body weight and consumption in the 21st PND were compared using reproducible methods ANOVA and LSD.

Results

The results are presented on the figures. As can be seen from figure 1, in the period from the 15th through the 21st PND opossums NS group continued to grow normally, while in all 5 MS groups were observed weight loss of the EAP is ot to the 17th PND, after which growth resumed in the group treated with the composition according to the invention (the diet with supplements 1), which showed the highest efficiency in the delay compensation of growth. In the period from 21st to 36th PND this trend accelerated in the group treated with the composition according to the invention, and this group at the 36th PND reached almost the same weight, that of the NS group (figure 2). From a comparative assessment can be seen that the MS group was fed the control diet (i.e. the same diet and NS group)reached a significantly lower body mass to 36 mu PND. From figure 2 you can see that the MS group receiving the diet with supplements 4 (prebiotic), also reached a final weight compared with the weight of the control and NS groups. The reason for this can be seen in figure 3, which shows that the feed intake in this group was consistently higher than the intake of all other groups in the period from 21st to 36th PND. However, this increased calorie intake't seem to translate into growth. From the comparative evaluation shows that the MS group receiving the diet with supplements 1, consume less amount of food than the MS group receiving the diet with the addition of 4, but comparable with other groups, including the group fed the control diet.

In addition, as can be seen from figure 4 and 5, delay compensation growth observed in the MS group, gender is of awsa diet with supplements 1, not associated with increased body mass index or the total mass of body fat, since these parameters were comparable to group settings, not subjected to stress. The authors concluded that nutritional composition comprising a combination of ingredients according to the present invention is effective in the compensation of stunted growth in young mammals, whose growth has slowed because they experience physical or mental stress, and that this combination is synergistic, because the net effect of the ingredients with the introduction of their animals individually less powerful than the total impact of the entire combination. In addition, the delay compensation growth is not associated with imbalances in the increase of body mass index, and therefore it should not increase the risk of obesity in later life.

1. The use of n-3 long-chain polyunsaturated fatty acids (n-3 DC PUFA), prebiotic fiber and probiotic bacterial strain for the production of nutrient composition, contributing to the compensation of stunting among the sick and convalescent young mammals.

2. The use according to claim 1, where the composition includes a source of lipids containing fatty acids and n-3 DC DHA is present in amount of at least 0.01% of the fatty acids in the lipids.

3. The use according to claim 1 or 2, where the nutrient composition further comprises n-6 DC PUFA.

4. The use according to claim 3, where n-6 DC DHA is present in amount of at least 0.01% of the fatty acids in the lipids.

5. The use according to claim 1, where prebiotic fibers are present in amounts of from 0.0001 to 0.05 g/g of composition.

6. The use according to claim 1, where the probiotic bacterial strain is present in an amount of from 103up to 1011CFU/g of composition.

7. The use according to claim 1, where the probiotic bacterial strain is Lactobacillus.

8. The use according to claim 7, where the Lactobacillus is Lactobacillus paracasei CNCMI-2116.

9. The use according to claim 7, where the Lactobacillus is Lactobacillus rhamnosus ADS 53103.

10. The use according to claim 1 or 6, where the probiotic bacterial strain is Bifidobacterium lactic CNCM I-3446.

11. The use according to claim 1 or 5, where prebiotic fibers are present in an amount of from 0.02 to 0.05 g/g of composition.

12. The use according to claim 1 or 5, where prebiotic fibers are fructo-oligosaccharides, inulin, galactooligosaccharides, gum Arabic, or mixtures thereof.

13. The application indicated in paragraph 12, where prebiotic fibers are a mixture of 40-60% gum Arabic, 10-20% of inulin and 30-40% of fructooligosaccharide.

14. The use according to claim 3, in which the ratio of n-6 DC PUFA to n-3 DC polyunsaturated fatty acids is from 1:2 to 8:1.

15. The use according to claim 1 or 14, in which n-3 DC DHA is docosahexaenoic Ki is lotai.

16. The use according to claim 4 or 14, in which the n-6 DC PUFA is arachidonic acid.

17. The use according to claim 9, where prebiotic fibers are calorigenically.

18. The use of claim 10, where prebiotic fibers are calorigenically.

19. The use of n-3 DC polyunsaturated fatty acids, prebiotic fiber and probiotic bacterial strain for the production of medicines, contributing to the compensation of stunting among the sick and convalescent young mammals.

20. The application of claim 19, where the drug includes a source of lipids containing fatty acids and n-3 DC DHA is present in amount of at least 0.01% of the fatty acids in the lipids.

21. The application of claim 19 or 20, where the medicinal product further comprises n-6 DC PUFA.

22. Use item 21, where n-6 DC DHA is present in amount of at least 0.01% of the fatty acids in the lipids.

23. The application of claim 19, where prebiotic fibers are present in amounts of from 0.0001 to 0.05 g/g of the drug.

24. The application of claim 19, where the probiotic bacterial strain is present in an amount of from 103up to 1011CFU/g of the drug.

25. The application of claim 19, where the probiotic bacterial strain is Lactobacillus.

26. Use A.25, where Lactobacillus is Lactobacillus paracasei CNCMI-116.

27. Use A.25, where Lactobacillus is Lactobacillus rhamnosus ADS 53103.

28. The application of claim 19 or 24, where the probiotic bacterial strain is Bifidobacterium lactic CNCM I-3446.

29. The application of claim 19 or 23, where prebiotic fiber is present in an amount of from 0.02 to 0.05 g/g of the drug.

30. The application of claim 19 or 23, where prebiotic fibers are fructo-oligosaccharides, inulin, galactooligosaccharides, gum Arabic, or mixtures thereof.

31. The application of article 30, where prebiotic fibers are a mixture of 40-60% gum Arabic, 10-20% of inulin and 30-40% of fructooligosaccharide.

32. Use item 21, in which the ratio of n-6 DC PUFA to n-3 DC polyunsaturated fatty acids is from 1:2 to 8:1.

33. The application of claim 19 or 32, in which n-3 DC DHA is docosahexaenoic acid.

34. The application of item 21 or 32, in which the n-6 DC PUFA is arachidonic acid.

35. The application of paragraph 24, where prebiotic fibers are calorigenically.

36. Use A.25 where prebiotic fibers are calorigenically.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology and specifically to methods of recycling household wastes. The method involves removing inorganic impurities, grinding, mixing wastes with an organic additive containing a culture of microorganisms and composting to obtain organic fertiliser. The organic additive used is compost based on poultry droppings, which is taken in amount of 300-500 kg per ton of wastes, and microbial strains Bacillus subtilis B-168, Bacillus mycoides B-691, Streptomyces sp. Ac-154, Mukor psychrophilus F-1441, Candida utilis Y-2441 in amount of 1·106-1·107 cells per millilitre per ton of poultry droppings.

EFFECT: simple process and low cost of processing household wastes.

1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to agriculture and can be used in processing cattle dung. The method involves formation of at least one pile of dung. Inoculating compost is added to the compost mass in amount of 10-15 kg/t. The compost mass is then moistened, biologically heated and periodically mixed. The inoculating compost used is compost based on poultry droppings and a consortium of microbial strains Bacillus subtilis B-168, Bacillus mycoides B-691, Streptomyces sp.Ac-154, Mukor psychrophilus F-1441, Candida utilis Y-2441 in amount of 1·106-1·107 cells per millilitre per ton of poultry droppings.

EFFECT: high effectiveness of the process, simple preparation of inoculating compost and low consumption of microorganisms.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to bioconversion of poultry wastes and can be used in production of ecologically clean effective fertiliser for agricultural crops. The method involves successive layering of droppings and a water-absorbing organic material, forming at least one pile and adding microorganisms in liquid form in form of a suspension, stirring the mixture, biological heating and aerobic fermentation of the mixture. Aerobic fermentation of the mixture is carried out until temperature of the mixture naturally drops to 25-30°C. The microorganisms used are consortium of Bacillus subtilis B-168, Bacillus mycoides B-691, Streptomyces sp. Ac-154, Mukor psychrophilus F-1441, Candida utilis Y-2441 in amount of 1·106-1·107 cells per millilitre per ton of poultry droppings.

EFFECT: cutting time for processing poultry droppings and improved quality of the biocompost.

2 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to agriculture and can be used in processing organic wastes, particularly manure and turf to obtain organic fertiliser. The method involves layering manure and water-absorbing material - turf, adding compost followed by aerobic composting at 50-60% moisture content of the mixture. The compost used is inoculating compost based on poultry droppings and a consortium of microbial strains Bacillus subtilis B-168, Bacillus mycoides B-691, Streptomyces sp. Ac-154, Mukor psychrophilus F-1441, Candida utilis Y-2441 in amount of 1·106-1·107 cells per millilitre per ton of poultry droppings. The inoculating compost is taken in weight ratio to the compost mixture of 1:20. Composting is carried out in piles.

EFFECT: simple process of making compost and obtaining compost with stable properties.

2 tbl, 2 ex

FIELD: food industry.

SUBSTANCE: nutritive medium contains a dry concentrate of salmon fish milt decoction, microbiological agar, sodium chloride, glucose, yeast extract, activated carbon (powder), distilled water at preset quantities and 30% egg yolk emulsion introduced after the nutritive medium sterilisation in an amount of 50 ml/l of the sterile medium.

EFFECT: invention allows to reduce the period of identification of listeria lecithinase activity.

3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: method involves DNA recovery from a clinical specimen followed by the PCR procedure with using group-specific primers to ompA Chlamydia trachomatis gene sites; the electrophoresis analysis of the amplification products is used to type Chlamydia trachomatis by B, C genotype groups and an intermediate group that is followed by the PCR procedure with using a number of type-specific primers selected by the Chlamydia trachomatis genotype group typing values; and the electrophoresis analysis of the amplification products is used to type Chlamydia trachomatis by A, B, C, D, E, F, G, J, Ja, H and K genotypes.

EFFECT: invention provides the information value and simplification of Chlamydia trachomatis typing in the infection caused by any Chlamydia trachomatis genotype combinations.

2 ex

FIELD: agriculture.

SUBSTANCE: strain Streptomyces cellulosae WH9, deposited in CGMCC under the number NO.2167 and used to produce a microbial fertiliser. The strain Aspergillus versicolor WH13, deposited in CGMCC under the number NO.2171 and used to produce a microbial fertiliser. The microbial phosphate fertiliser contains a product of fermentation of a microbial composition containing the following four microorganisms: a strain Bacillus subtilis WH2 (CGMCC NO.0395.2), a strain Bacillus licheniformis WH4 (CGMCC NO.0395.4), a strain Streptomyces cellulosae WH9 and a strain Aspergillus versicolor WH13. Also the method is provided to manufacture the specified microbial phosphate fertiliser, where production of the specified microbial phosphate fertiliser may include using the ground phosphate rock containing 8%-12% P2O5.

EFFECT: improved properties of the strain.

8 cl, 3 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: as antigens, vaccine contains a cell suspension of pure culture of E. coli colibacillosis, Str. pneumoniae streptococcus agents and rabbit hemorrhagic disease virus prepared by sampling the affected organs of dead rabbits of a local epizootic centre.

EFFECT: invention provides higher specificity and efficacy of the associated colibacillosis, streptococcus and rabbit viral hemorrhagic disease vaccine eliminating an adverse side effect on animals, and also can be used in research and manufacturing facilities involved in biological engineering.

1 tbl

FIELD: medicine.

SUBSTANCE: affected organs of dead rabbits from a local epizootic centre are sampled to prepare a suspension, and differential-diagnostic mediums are inoculated; pure-growth agents are recovered; separately, E. coli, Str. pneumoniae cultures are grown in a meat-peptone broth with glucose added to the concentration of 0.2% and titre 4-5 billion microbial cells in 1 cm3; then rabbits are infected with a hemorrhagic disease virus of the activity not less than 103.0 LD50/cm3, and liver of dead rabbits is used to prepare 10-15% suspension; thereafter the agent cultures are separately inactivated with formalin to the final concentration no more than 0.4% at temperature 37°C for 4 days or less; then the mixed inactivated cultures are added with an adjuvant presented by aluminium hydroxide gel in the amount of 20 vol %; the end product is thoroughly mixed before packing.

EFFECT: invention provides producing a harmless, high-immunogenic storage-stable vaccine.

1 tbl

FIELD: medicine.

SUBSTANCE: recombinant method is used to produce a microorganism of Mycobacterium tuberculosis complex which involves phoP gene inactivation or deletion and fadD26 gene inactivation or deletion. The produced microorganism is used for preventing tuberculosis in humans and animals.

EFFECT: invention allows producing the vaccine microorganism showing the properties of high attenuation and immune protection against tuberculous infection.

7 cl, 27 dwg, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared group of inventions relates to medicine. What is offered is using the Enterococcus faecium M (All-Russian collection of industrial microorganisms B-3490) and/or Enterococcus faecium M-3185 (VKPM B-3491) strains for preparing a composition, an agent or a preparation for treating viral hepatitis. The composition, the agent or the preparation for treating viral hepatitis contains an effective amount of the Enterococcus faecium M (All-Russian collection of industrial microorganisms B-3490) strain and/or an amount of the Enterococcus faecium M-3185 (All-Russian collection of industrial microorganisms B-3491) strain, and a pharmaceutically acceptable carrier. The composition, the agent or the preparation based on the Enterococcus faecium M (All-Russian collection of industrial microorganisms B-3490) and/or Enterococcus faecium M-3185 (All-Russian collection of industrial microorganisms B-3491) strains are administered orally in an effective single dose one to three times a day for 10-180 days.

EFFECT: compositions and methods have high therapeutic effectiveness, the patients show no such intoxication symptoms as dizziness and sleepiness; general state of health is normalised more rapidly.

2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology and medicine, and represents a solid composition for vaginal and rectal introduction of biologically active substances after said composition is dissolved/suspended in a hydrophilic fluid medium containing: at least a biologically active substance selected from a group consisting of microorganisms, and at least a viscosity agent representing tara gum which is added to said composition so that after dissolved/suspended in said fluid medium, its percentage makes 0.05% and more (wt/vol).

EFFECT: invention provides preparing the composition which after dissolved/suspended in the hydrophilic fluid has the adequate viscosity and does not flow out the body that promotes effective colonisation of the rectal and/or vaginal mucosa.

13 cl, 5 tbl, 4 dwg

FIELD: medicine, dietology.

SUBSTANCE: invention relates to medicine in particular to dietology and the methods of application of dietic nutritional compositions; the nutritional composition and dietic ration contain at least one α-glycosidase inhibitor, at least one prebiotic and/or probiotic; to be more exact the above α-glycosidase inhibitor is the extract of Touti; the application of the specified composition is designated for curing various derangements including diabetes, hyperlipemia, hyperadiposis, metabolic syndrome/X syndrome, COPD, malabsorption syndrome, Crohn's disease, diarrhea, coprostasia, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic fatty liver disease, polycystic ovarian syndrome as well as that connected to infertility and erectile dysfunction; besides, α-glycosidase inhibitors and in particular the Touti extract can be applied to contribute to the recovery of patients being under the intensive therapy as well as to the general healing of wounds; besides, α-glycosidase inhibitors including the Touti extract can be used for enhancement of athletic performance.

EFFECT: invention ensures the increase of the concentration of GLP-1 and GLP-2 in blood plasm without side effects.

32 cl

FIELD: biochemistry.

SUBSTANCE: method includes separate culturing of strains of lactic bacteria and bifidus bacteria on bouillon containing digest of casein produced by hydrolysis using cattle pancreas, carbohydrate component containing lactose and raffinose in ratio 1:1. Raffinose is both a carbohydrate component and probiotic component. The medium contains peptone, agar-agar, ascorbic acid and distilled water. The mixture of strains is added to sorbing component prepacked in vial in proportion of ½ - ¼ from total volume of created complex system. Process of immobilization on sorbent - Litovit M dietary supplement is performed at temperature +6°C±2°C for 18-24 hours.

EFFECT: production of immobilized synbiotic product with high content of live microbial cells, several strains of lactic bacteria and bifidus bacteria with increased protective and treatment activity.

3 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to strain of microorganism, ensuring recovery of soil and animal gastrointestinal tract (GIT) microbiocenosis, possessing antibacterial and fungicidal activity, and to based on them preparation form and can be used in biotechnology, veterinary medicine and plant protection. Strains Bacillus licheniformis IC-831-1-2, Bacillus licheniformis IC-832-1-2, Bacillus licheniformis IC-833-1-2, Bacillus licheniformis IC-834-1-2 are obtained by method of directed selection and are deposited in All-Russian Collection of Industrial Microorganisms FSUE GosNIIGenetika under registration numbers All-Russian collection of industrial microorganisms respectively: B-10561, B-10562, B-10563 and B-10564. Preparation is characterised by containing filling agent with bacteria biomass in spore form Bacillus licheniformis All-Russian collection of industrial microorganisms B-10561, or All-Russian collection of industrial microorganisms B-10562, or All-Russian collection of industrial microorganisms B-10563, or All-Russian collection of industrial microorganisms B-10564, or their mixture with titre of each bacteria strain not less than 1·103 CFU/g or 1·103 CFU/ml. As filling agent it contains water or powder-like sorbent.

EFFECT: invention makes it possible to increase efficiency of restoring soil, animal GIT microbiocenosis and extend spectrum of antibacterial and fungicidal activity.

9 cl, 9 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is offered in application of at least one strain of probiotic bacteria specified in Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, Lactobacillus plantarum HEAL 99, DSM 15316, Lactobacillus paracasei 8700:2, DSM 13434 and Lactobacillus paracasei 02A, DSM13432 for preparing a composition for treating and/or preventing a viral infection caused by 'cold' virus, and a related method for treating and/or preventing. A number of days for which 'cold' symptoms are experienced has been also reduced in a group of patients having been taking a probiotic.

EFFECT: what is shown is intensified immune protection against antiviral infection that promotes decreasing 'cold' episodes in comparison with the controls.

16 cl, 13 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a method of sublimation dehydration of high-disperse biologically active materials found in a microdrop state characterised by the fact that the microdrop powder is frozen at temperature -35°C to -45°C for 1.5 to 8 h, and then dehydrated.

EFFECT: invention provides reduced duration of the dehydration process of biologically active materials.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents a method for producing fine-grained biologically active materials containing active substances, characterised by the fact that the liquid with biologically active substances is dispersed to the microdrop state in a layer of dry fine-grained inert hydrophobic aerosil in the proportion 10:1.5 to 10:6, to form thereby liquid microdrops surrounded by hydrophobic aerosil particles and powdered which, if necessary, are dried by a technologically acceptable method.

EFFECT: invention provides increasing dispersion of biologically active materials.

11 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a method of combination dehydratation of high-disperse biologically active materials containing active substances in a liquid phase, implemented in stages and differing by the fact that the liquid phase with the active substance in a microdrop state stabilised by a dry high-disperse hydrophobic disconnector in ratio 1:3-1:22, is dehydrated initially at atmospheric pressure and then by mixing with a high-absorbency sorbent with residual moisture less than 1% and dried up if needed.

EFFECT: invention provides higher activity of the active substances.

9 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry and represents a preparation containing a biologically active substance, characterised by the fact that it contains a powder based on dried microdrops of the active substance stabilised by a dry high-disperse inert hydrophobic disconnector representing silicone dioxide with the components of the preparation being in the certain mass ratio per 1 g of the preparation.

EFFECT: invention provides higher dispersity of the preparation and preservation of the active substances in the preparation.

13 ex, 2 tbl

FIELD: food industry.

SUBSTANCE: invention relates to food industry, in particular, to biologically active food additives. The biologically active food additive consists of an active component and accessory substances. The active substance is represented by a concentrated milky-wax ripeness walnut extract produced by way of walnut extract evaporation till moisture content is 30%. The accessory substances are represented by PEG-400 and glycerol. The additive contains the components at the following ratio, wt %: concentrated milky-wax ripeness walnut extract - 75-78, PEG-400 - 14-17, glycerol - 7-9. The biologically active food additive is encapsulated and produced in the form of soft gelatinous capsules.

EFFECT: invention allows to produce a new biologically active food additive being a source of flavonoids, tannins and vitamin C and having high biological activity.

2 tbl, 1 ex

Up!